

## ASX / MEDIA ANNOUNCEMENT

30 April 2020

### Integrated AsthmaCare Telehealth Service with Practice Innovators for wheezo®

**Respiri Limited (ASX:RSH)** ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management, today announces it has entered into partnering discussions with Practice Innovators International Pte Ltd ("PII") that will result in the integration of Respiri's wheezo® eHealth Software as a Service (SaaS) monitoring platform into PII Australia's proprietary telehealth platform GPNow. The parties are committed to entering into a binding Joint Development Agreement (JDA) during the current quarter, with an intention to conduct field trials together in Q3 2020 with a view to launching an integrated AsthmaCare Telehealth Service offering in Q4 2020.

PII has recently launched CoronavirusCare; a secure end to end encrypted ("E2EE") telehealth service that provides contact-free video consultations with medical professionals, for advice and support during the current crisis and is bulk-billable through Medicare. Unlike other telehealth providers, PII is a business to business (B2B) platform provider with operations in Australia but plans for Singapore, Malaysia, Indonesia and the Philippines thus providing Respiri with commercial opportunities in Southeast Asia.

Under the terms of the JDA to be finalised, Respiri and PII will be responsible for the integration of wheezo SaaS into the GPNow platform and for the training its B2B partners enabling easy access to the wheezo SaaS and medical device. This development pathway will facilitate the asthma care beyond the clinic.

Mr Marjan Mikel, CEO & Managing Director of Respiri said "Respiri is pleased to have entered into commercial discussions with PII in the rapidly growing telehealth field. The progression to a binding agreement with PII will further leverage our telehealth capability in Australia and help deliver better respiratory care to some of our country's most needy people, help contribute to closing the indigenous health gap and progressively move into South East Asia as PII expands its business internationally."

Mr Robert Hicken, Founder and CEO of PII commented "Prevention is always better than cure, Respiri's amazing "wheezo" technology allows asthmatics to measure, manage and monitor chronic conditions BEFORE an acute attack occurs. Marrying Respiri's world-class technology with our private "contact free" telehealth service such as GPNow [www.gpnow.net](http://www.gpnow.net) represents a powerful, "patient-centric", safe and secure vehicle with enormous reach for delivery of comprehensive AsthmaCare plans. Leveraging Respiri analytics at "point of care" together via regular virtual consultations with a GPNow certified doctor or respiratory specialist as part of an ongoing telehealth AsthmaCare plan creates a powerful combination to help asthmatics both locally and internationally live with the challenge of asthma. Improving Patient Care is our mantra and the GPNow team is excited at the prospect of partnering with Respiri to achieve this goal for those affected with respiratory issues."

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement dated 30 April 2020 has been authorised for release by the Board of Directors of Respiri Limited.*

## About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)

## About Practice Innovators International Pty Ltd

Established in March 2017, Practice Innovators International (PII Australia) practices "effective altruism" with the aim to provide better access to medical professionals for patients, regardless of their location. The GPNow telehealth platform is currently engaged with Aged Care facilities, Aboriginal Groups, Bushfire-affected communities and Spinal Cord Injuries Australia whose healthcare services are funded by the National Disability Insurance Scheme (NDIS). GPNow provides private, safe, secure access to AHPRA certified medical professional anywhere, anytime. GPNow is a member of the Medical Software Industry Association.

In Australia, PII clients include indigenous community groups providing funded telehealth care to these remotely located Australians where the incidence of asthma is 16.5%, which is significantly higher than other Australians (10.2%). Further, indigenous Australians are twice as likely to be hospitalised for asthma and three times as likely to die of asthma as other Australians.

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.